Probi’s dietary supplements to be launched in Spain

Probi’s partner Institut Rosell has signed an agreement giving the pharmaceutical company SALVAT an exclusive right to sell a dietary supplement based on Probi’s bacteria, Lp 299v in Spain. The first order from SALVAT has already been received and will affect Probi’s Q4 2008 results positively.

“We are very pleased that our strategy of offering turnkey probiotic products addressing specific health concerns has attracted SALVAT, one of the leading pharmaceutical companies in the Spanish gastroenterology market. Spain is one of the largest and most dynamic markets in Europe and we are very excited that we are able to launch in 2008,” says Michael Oredsson, CEO of Probi.

SALVAT is a medium sized, privately owned pharmaceutical company that successfully develops, manufactures and markets high-quality pharmaceuticals. One of the main business areas is gastroenterology. The launch of Protransitus Lp, based on Probi’s strain Lp 299v, is an important step for SALVAT. Lp299v will broaden SALVAT´s portfolio of probiotics with a scientifically proven effect and will further strengthen their position as one of the leading players in the Spanish gastroenterology market.

Dietary supplements based on Probi’s probiotics are now sold or in the process of being launched in more than 25 countries.

“We are working both on our own and together with Institut Rosell to further expand distribution and sales of dietary supplements with Lp299v and we believe this process will continue to be successful,” says Michael Oredsson, CEO of Probi.


For more information, please contact:
Michael Oredsson, CEO, Probi, phone. +46 46 286 89 23 or mobile +46 707 18 89 30
e-mail: michael.oredsson@probi.se
Niklas Bjärum, VP Marketing & Sales, Probi phone. +46 46 286 89 67 or mobile +46 705 38 88 64,
e-mail: niklas.bjarum@probi.se
Olivier Clech, President, Institut Rosell, phone: + 33 611 30 26 31

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links